CRGX vs. ABCL, PRTA, BCAX, CRON, IMNM, NUVB, MLYS, AVBP, BCYC, and CVAC
Should you be buying CARGO Therapeutics stock or one of its competitors? The main competitors of CARGO Therapeutics include AbCellera Biologics (ABCL), Prothena (PRTA), Bicara Therapeutics (BCAX), Cronos Group (CRON), Immunome (IMNM), Nuvation Bio (NUVB), Mineralys Therapeutics (MLYS), ArriVent BioPharma (AVBP), Bicycle Therapeutics (BCYC), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.
CARGO Therapeutics vs.
AbCellera Biologics (NASDAQ:ABCL) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
CARGO Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than CARGO Therapeutics, indicating that it is currently the more affordable of the two stocks.
AbCellera Biologics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, CARGO Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.
CARGO Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat CARGO Therapeutics' return on equity.
AbCellera Biologics currently has a consensus price target of $7.00, indicating a potential upside of 176.68%. CARGO Therapeutics has a consensus price target of $15.00, indicating a potential upside of 258.85%. Given CARGO Therapeutics' higher possible upside, analysts clearly believe CARGO Therapeutics is more favorable than AbCellera Biologics.
In the previous week, CARGO Therapeutics had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 4 mentions for CARGO Therapeutics and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.11 beat CARGO Therapeutics' score of -0.07 indicating that AbCellera Biologics is being referred to more favorably in the media.
61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 28.0% of AbCellera Biologics shares are owned by company insiders. Comparatively, 1.4% of CARGO Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
AbCellera Biologics received 41 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. Likewise, 75.34% of users gave AbCellera Biologics an outperform vote while only 66.67% of users gave CARGO Therapeutics an outperform vote.
Summary
AbCellera Biologics beats CARGO Therapeutics on 10 of the 17 factors compared between the two stocks.
Get CARGO Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CARGO Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRGX) was last updated on 3/26/2025 by MarketBeat.com Staff
